Patent directory · USPTO A61K / A61P
Patents matching “OVID THERAPEUTICS INC.”
48 pharma patents match "OVID THERAPEUTICS INC." in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.
Quick answer
This filtered view shows 48 pharmaceutical patents matching "OVID THERAPEUTICS INC." in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.
Patent results
-
US 12285397
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 12144801
Methods and compositions for treatment of epileptic disorders
granted -
US 12109201
Methods and compositions for treatment of epileptic disorders
granted -
US 11918551
Methods of treating seizure disorders and Prader-Willi syndrome
granted -
US 11918563
Methods and compositions for treatment of epileptic disorders
granted -
US 11903930
Methods and compositions for treatment of epileptic disorders
granted -
US 11806336
Methods and compositions for treatment of epileptic disorders
granted -
US 11771671
Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
granted -
US 11761006
Use of MIR101 or MIR128 in the treatment of seizure disorders
granted -
US 11690829
Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
granted -
US 11660277
Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 11395817
Methods and compositions for treatment of epileptic disorders
granted -
US 11364228
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
granted -
US 11291658
Use of gaboxadol in the treatment of diabetes and related conditions
granted -
US 11278529
Methods for treating aggression associated with Alzheimer's disease
granted -
US 11096929
Methods of treating developmental disorders with gaboxadol
granted -
US 11090293
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
granted -
US 10925879
Methods of treating developmental disorders and/or seizure disorders with etifoxine
granted -
US 10870855
Use of MIR101 or MIR128 in the treatment of seizure disorders
granted -
US 10813899
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
granted -
US 10813918
Use of Gaboxadol in the treatment of diabetes and related conditions
granted -
US 10799485
Methods and compositions for treatment of epileptic disorders
granted -
US 10765646
Methods of treating developmental encephalopathies
granted -
US 10765666
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
granted